Prosight Management, LP - REATA PHARMACEUTICALS INC ownership

REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 212 filers reported holding REATA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.8%.

Quarter-by-quarter ownership
Prosight Management, LP ownership history of REATA PHARMACEUTICALS INC
ValueSharesWeighting
Q4 2020$1,497,000
-86.6%
12,112
-89.4%
0.69%
-87.0%
Q3 2020$11,160,000
-12.9%
114,554
+39.5%
5.31%
-3.5%
Q2 2020$12,809,000
+18.3%
82,100
+9.5%
5.50%
+8.6%
Q1 2020$10,826,000
-15.8%
75,000
+19.2%
5.06%
-10.4%
Q4 2019$12,859,000
+155.9%
62,900
+0.5%
5.65%
+102.6%
Q3 2019$5,025,000
-57.4%
62,591
-49.9%
2.79%
-53.1%
Q2 2019$11,790,000
-21.5%
124,965
-28.9%
5.94%
-9.5%
Q1 2019$15,017,000
+5.8%
175,700
-30.6%
6.57%
-10.3%
Q4 2018$14,193,000
+116.6%
253,000
+215.6%
7.33%
+100.5%
Q3 2018$6,553,000
+125.5%
80,155
-3.5%
3.65%
+71.5%
Q2 2018$2,906,000
-52.4%
83,094
-72.1%
2.13%
-44.4%
Q1 2018$6,107,000
+24.7%
297,750
+72.2%
3.83%
+6.4%
Q4 2017$4,896,000172,8973.60%
Other shareholders
REATA PHARMACEUTICALS INC shareholders Q2 2020
NameSharesValueWeighting ↓
Conrad N. Hilton Foundation 63,481$7,847,000100.00%
CPMG Inc 2,896,901$358,115,00055.16%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 140,000$17,307,00026.62%
Corriente Advisors, LLC 525,000$64,901,00015.45%
DUMAC, INC. 76,050$9,401,0007.33%
MADDEN SECURITIES Corp 35,152$4,345,0002.80%
Biondo Investment Advisors, LLC 113,692$14,055,0002.69%
Duquesne Family Office 749,897$92,702,0002.50%
LBJ Family Wealth Advisors, Ltd. 30,368$3,754,0002.44%
Integral Health Asset Management, LLC 50,000$6,181,0001.84%
View complete list of REATA PHARMACEUTICALS INC shareholders